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to my father 
ABSTRACT 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the 
industrialized countries and a growing concern for the developing world. The underlying 
cause of almost all CVD is atherosclerosis, a process that is characterized by a low-grade 
inflammation in the artery walls. This inflammation is believed to be initiated by 
components of low density lipoproteins which, upon oxidation, display pro-inflammatory 
self-neo epitopes such as malonyldialdehyde (MDA) and phosphorylcholine (PC). 
Antibodies directed against the PC-epitope (anti-PC) have been researched for several 
decades but the relatively recent realization that these antibodies also recognize oxidized 
phospholipids has revolutionized the field and opened up a whole new avenue of 
investigation. Anti-PC has been shown to aid the clearance of apoptotic cells and prevent 
the formation of foam cells by clearing oxidized low density lipoprotein.  Murine studies 
with PC-vaccination have shown strong beneficial effects on experimental atherosclerosis 
in vivo and human epidemiology has consistently linked anti-PC insufficiency to CVD.  
 
All humans have detectable anti-PC IgM in serum, though the concentration varies 
greatly between individuals. Our group has previously shown that people with low 
serum/plasma levels of anti-PC IgM have increased risk of CVD and the subgroup 
analysis had indicated that this association was particular strong with regard to the 
incidence of stroke. In paper I, we tested this hypothesis in a stroke material from 
northern Sweden.  A significant association between low plasma level of anti-PC IgM at 
baseline and incident stroke was seen for the whole group at anti-PC levels below the 30th 
percentile (OR 1.62; CI 1.11 to 2.35). Analyses of gender-specific associations indicated 
fairly strong associations for females, especially at the lowest 30th percentile (OR 2.65; 
CI 1.41 to 4.95). However, no association was noted for men. 
 
Paper II focused on the properties of different anti-PC antibody classes/subclasses. We 
report that anti-PC IgM, IgA and IgG1 (but not IgG2) were negatively associated with 
IMT-progression, which is a surrogate marker for atherosclerosis development.  
Examination of binding profiles revealed that the protective isotypes (IgM, IgA and 
IgG1) have a different fine-specificity than the non-protective IgG2. Analysis of serum 
samples taken four years apart in study participants showed that anti-PC IgM titers, 
essentially, do not change over time. In this paper, we also demonstrate that anti-PC 
IgM inhibits LPC-induced cell death in vitro and propose that this is yet another 
protective mechanism. 
 
For paper III, I had successfully designed a PC-specific probe to identify, isolate and 
characterize PC-reactive B cells from ten healthy human donors. We found that all ten 
had mounted somatically mutated antibodies towards PC utilizing a broad variety of 
immunoglobulin-genes. PC-reactive B cells were primarily found in the IgM+ memory 
subset though significant numbers were also detected among naïve, IgG+ and 
CD27+CD43+ B cells. From the isolated B cells, we derived several human monoclonal 
antibodies (mAbs) with proven PC specificity.  
 
In conclusion, the future of CVD treatment lies with immunomodulation and the premise 
of this thesis represents one avenue of research in the quest for novel diagnostic tools and 
improved treatment options. My work has focused on understanding the properties and 
molecular ontogeny of human anti-PC antibodies. Though this thesis represents one 
important step in the direction of clinical application, much more research is needed 
before we will see use of anti-PC mAbs or PC-vaccination in the treatment of patients.  
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1. INTRODUCTION 
 
Cardiovascular disease (CVD) is the leading cause of morbidity and 
mortality the industrialized countries and a growing concern for the 
developing world. During the past century, research has made enormous 
strides in understanding this disease from a clinical perspective. At 
present, medical doctors have a multitude of proven drugs at their disposal 
and a good understanding of some major risk factors for developing CVD 
(smoking, obesity, hypertension, diabetes etc). However, the molecular 
understanding of atherosclerosis, which is the underlying cause behind 
almost all CVD is still patchy and a lot of research is currently devoted to 
studying this process for the purpose of identifying new risk 
factors/markers and finding novel targets for a new generation of drugs.  
 
The scientific work in this thesis represents one avenue of research in the 
quest for better diagnostic tools and treatment options for patients with 
CVD. The contents revolve around the proposed protective role of 
phosphorylcholine antibodies (anti-PC) in CVD, their properties and their 
origin. This introduction will facilitate reader understanding of the 
experimental and epidemiological studies performed by providing a brief 
overview of the immune system, atherosclerosis and anti-PC.  
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1.1 THE IMMUNE SYSTEM 
The main purpose of the immune system is to defend the organism against 
invading pathogens such as bacteria, fungi, parasites and viruses. 
However, there are also several other vital purposes. One such auxiliary 
purpose is the surveillance of endogenous processes in order to locate and 
eliminate tumor cells. Another proposed function of the immune system is 
the clearance of apoptotic cells and oxidatively damaged molecules. 
Figure 1 provides a schematic overview of the immune system, showing 
its major branches.  
 
Figure 1. The organization of the immune system.  
 
 
1.1.1 Innate immunity 
All multicellular organisms possess a pre-programmed system for 
eliminating tumor cells, invading microbes and cleaning up damaged 
endogenous molecules/cells. The receptors and effector molecules of 
innate immunity are germline encoded and this system represents the 
organisms’ first line of defense. These are the components of the innate 
immune system: 
1. An epithelial barrier covers the entire interface between the body 
and the outside world. Besides the obvious physical barrier function, 
epithelial cells are also capable of producing antimicrobial peptides 
and enzymes among many things. This layer is also home to many 
dendritic cells (discussed below) and the mast cells, which are 
important in fighting parasites and mediating allergic reactions.  
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2. The complement system is a collection of circulating membrane-
associated proteins, many of which possess proteolytic activity. 
Complement does not attack endogenous cells because these exhibit 
regulatory proteins on their surface. Bacteria lack these regulatory 
proteins and after complement associates with a microbial surface, a 
cascade is activated which results in the formation of pores and 
subsequently bacterial lysis and death. This microbial surface 
association may be spontaneous but it can be enhanced by the 
presence of antibodies on the microbe. 
3. Phagocytes can be subdivided into neutrophils, dendritic cells and 
monocytes/macrophages. They ingest microbes and clean tissues by 
removing cell debris and dead cells. Engulfed pathogens are 
subjected to killing by reactive oxygen species (ROS) and 
degradation by enzymes. Neutrophils are the most abundant class of 
immune cells in circulation. They are quickly mobilized to the site 
of infection, where they engulf microbes and die after a few hours. 
Monocytes are less abundant in circulation but once they enter 
extravascular tissue, they differentiate into macrophages which live 
for long periods of time. As a general rule, monocytes/macrophages 
are involved in chronic inflammatory conditions, e.g. atherosclerosis 
and rheumatoid arthritis whereas neutrophils are associated with 
acute inflammation.  
Dendritic cells are the precursors professional antigen presenting 
cells (APCs) that connect the innate with the adaptive immune 
system.  These cells share genealogical lineage with monocytes and 
reside in extravascular tissue, where their main purpose is to detect 
foreign molecules by engulfing particles around them and after 
degradation, initiate powerful adaptive immune responses by 
presenting these non-self peptides to lymphocytes of the adaptive 
immune system. 
4. Innate lymphocytes can be broadly divided into NK cells, NKT 
cells, γδ T cells and B1 cells. Natural Killer cells or NK cells have 
been extensively studied, since their discovery at Karolinska 
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Institutet many years ago. They primarily respond to intracellular 
microbes by killing infected host cells but are also believed to be 
important in removing tumor cells. Natural Killer T (NKT) cells and 
γδ T cells are less well understood but are believed to recognize 
non-peptide antigens, such as polysaccharides and phospholipids.  
B1 cells are perhaps the most enigmatic among the innate 
lymphocytes. Theoretically speaking, these are B cells that possess a 
limited set of gene rearrangements for their antigen receptor and 
spontaneously secrete “natural” IgM antibodies without external 
antigen stimulation. Furthermore, B1 cells are supposed to be 
primarily located in the peritoneal cavity and respond to lipid and 
polysaccharide antigens. In textbooks as well as many research 
papers, phosphorylcholine (PC) is often portrayed as a prototypic 
B1 antigen and antibodies against PC (anti-PC) are assumed to be 
the product of B1 cells.  
One major problem in this research field is that nobody has 
convincingly shown that B1 cells exist in humans. All research on 
B1 cells has been done in mice and the data has simply been 
extrapolated to humans. While mice unequivocally have a 
population of CD5+ B cells that fulfill the above-mentioned 
description; in humans CD5 does not distinguish innate B1 cells 
from regular B cells (B2 cells). In 2011, Griffin et al published a 
paper in the prestigious Journal of Experimental Medicine, where 
they claim that human B1 cells are CD20+CD27+CD43+ and CD70- 
(Griffin, Holodick et al. 2011). However, their data could not be 
reproduced by renowned fellow scientists in letters to the 
aforementioned journal (Descatoire, Weill et al. 2011). Our group 
has not been able to fully reproduce their data either, as will be 
discussed later. In conclusion, the presence of B1 cells in humans is 
an interesting but highly controversial subject. This is also an issue 
that is intimately linked with this thesis since anti-PC antibodies are 
supposedly products of B1 cells.  
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The components of innate immunity recognize evolutionarily conserved 
structures that are shared by various classes of pathogens but absent from 
healthy endogenous cells. These structures represent “danger signals” or 
pathogen associated molecular patterns (PAMPs), which the immune 
system has evolved to identify. Examples of such foreign PAMPs are 
bacterial lipopolysaccharide (LPS), double stranded RNA and 
unmethylated CpG nucleotides, which are common in bacterial DNA but 
absent in mammalian DNA. These structures are detected by pattern 
recognition receptors (PRR), which are germline encoded and are capable 
of recognizing approximately 103 different patterns. Examples of PRRs are 
Toll like receptors (TLRs), scavenger receptors (ScRs). 
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1.1.2 Adaptive immunity 
Whenever pathogens manage to breach the strong defense mechanisms 
that constitute the innate immunity, the hope of the organism lies with its 
adaptive immunity. Unlike the very rapid innate responses (immediate to a 
few hours), the more powerful adaptive immune system is slow to 
mobilize (days to weeks). This system consists of lymphocytes and their 
products; it has a very high degree of specificity and can recognize and 
respond to literally billions of different antigens.  
 
The adaptive immunity is divided into cellular immunity mediated by 
cytotoxic T cells expressing T cell receptors (TCR) and humoral immunity, 
which consists of B cells producing antibodies. Central to both systems are 
the dendritic cells (DCs) briefly mentioned in the previous section on 
innate immunity. Tissue residing DCs are constantly sampling/monitoring 
the extra cellular fluid around them. During a localized infection, the 
microbes will inevitably trip the pattern recognition receptors (PRRs) of 
the DCs, thus triggering production of cytokines such as tumor necrosis 
factor alpha (TNF-α) and the migration of DCs to the local lymph node. 
With them, the DCs bring microbial antigens that they have acquired 
either through pinocytosis of soluble antigens or phagocytosis of entire 
microbes. During the journey to the lymph node, the DCs mature into 
professional antigen presenting cells. 
 
The DCs break down everything they engulf and present the fragments on 
their surface using antigen presenting molecules called MHC class II. A 
foreign peptide presented on the MHC:peptide complex will be recognized 
by T lymphocytes specific for that particular epitope, at the lymph node, 
and result in the activation of these T cells. Another group of important 
antigen presenting molecules on DCs is the CD1 family which is believed 
to present lipid antigens.  
 
1.1.2.1 Humoral immunity 
Antibodies are the effector molecules of the humoral immunity. The basic 
antibody unit consists of four polypeptide chains, two identical long heavy 
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chains (H) and two identical short light chains (L) which are combined to 
form a Y-like structure. The light chains may be either of the Kappa (κ) or 
the Lambda (λ) type.  
 
This basic unit has one constant 
(C) region which is shared by all 
antibodies of the same class. 
The other part of this 
macromolecule is the variable 
(V) region, which is used to 
bind antigen. The composition 
of the V-region is unique for 
each antibody clone and 
differentiates it from other 
antibody clones.  
 
The V-region is formed by 
combining a part from the heavy chain (VH) and one part from the light 
chain (VL). Each chain has three important complementary determining 
regions (CDRs), which together make up most of the antigen binding 
pockets. Of these six CDRs, the most important for antigen binding and 
incidentally also the most heterogeneous region is the heavy chain CDR3. 
The peptide sequence at this site so diverse that is often used to distinguish 
between different antibody clones much like fingerprints are utilized to 
identify people.  
 
The human body can produce an almost infinite number of different 
antibody-specificities and this variability is attained by two different 
mechanisms: 
 
1. Combinatorial diversity. The human body has roughly 45 
functional heavy V-genes, 23 D-genes and 6 heavy J-gene 
segments. One heavy chain is formed by combining one segment 
Figure 2. Basic antibody structure 
 
 
Constant region 
 
 
 
 
  
Variable region 
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from each of the three gene-families. Hence, it is mathematically 
possible to generate 45×23×6 = 6210 different heavy chains.  
 
As above mentioned, there are two types of light chains, Kappa and 
Lambda. Kappa light chains are formed by combining one of 35 
Vκ-genes with one of 5 Jκ-genes (35×5 = 175 possibilities). 
Lambda chains are formed by combining one of 33 Vλ-genes with 
one of 5 Jλ-genes (33×5 = 165 possibilities). Notice that there are no 
D-gene segments on light chains. 
 
Finally, by joining 6210 possible heavy chains with either 175 
possible Kappa chains or 165 possible Lambda chains, we arrive at 
6210×175 + 6210×165 ≈ 2.1 million possible antibody Variable-
regions.  
 
Figure 3. The generation of heavy chain combinatorial diversity. 
 
2. Junctional diversity. The somatic recombination of V, D and J 
(heavy chains) or only V and J (light chains) is mediated by a 
collection of enzymes which together are referred to as the V(D)J-
recombinase. When the chosen V, (D) and J gene segments are cut 
from the germline DNA and combined together, additional diversity 
is introduced by enzymes which may add or delete a random 
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number of nucleotides at the interface between two chosen gene-
segments, often leading to frameshifts. This junction region encodes 
the previously-mentioned highly variable CDR3-region, which is so 
important for antigen recognition. Adding junctional diversity on 
top of combinatorial diversity creates an almost infinite number of 
possible antibody specificities (1011).  
 
The generation of diversity occurs in the bone marrow at the pre-B cell 
state. Progenitor cells committed to the B cell lineage first develop into 
pro-B cells before maturing into pre-B cells. Upon completion of 
recombination, the expression of functional IgM initiates a signaling 
cascade that silences the V(D)J-recombinase and heralds the advent of the 
immature B cell. After also acquiring IgD on its surface, the B cell is 
considered mature. 
 
Table 1. Steps in the maturation of B lymphocytes  
 Progenitor 
cell 
Pro-B 
cell 
Pre-B cell Immature B 
cell 
Mature B 
cell 
Immunoglobulin  
DNA 
Germline 
DNA 
Germline 
DNA 
Recombination 
in progress 
Recombined 
DNA 
Recombined 
DNA 
Immunoglobulin  
expression 
None None 
Cytoplasmic 
heavy chains 
Surface IgM 
Surface IgM 
and IgD 
 
There are mainly two check-points in the development of the B cells that 
assures the generation of healthy, non-autoreactive B cells. 
 
1.  If recombination of the germline DNA at the pre-B cell stage fails 
to produce functional proteins, the nascent B cell enters apoptosis.  
 
2. Immature B cells that through recombination have acquired 
functional antibodies that bind native molecules present in the bone 
marrow with high affinity either die by apoptosis or may activate 
the recombinase machinery again to try to obtain a different non-
autoreactive specificity by fashioning a new light chain.  
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Antibodies are divided into five major classes based on the heavy chain 
constant region: IgM, IgD, IgA, IgE and IgG. The IgA and IgG classes are 
further subdivided into subclasses: IgA1, IgA2, IgG1, IgG2, IgG3 and 
IgG4. Each antibody type has its own special abilities, which are 
conferred/determined by the antibody Fc-region. This part is located at the 
tail of the Y-like antibody molecule. For example, only the Fc-region of 
IgE is able to dock to mast cells Fcε-receptor with high affinity. 
 
Table 2. The immunoglobulin classes and their function 
Function IgM IgD IgG1 IgG2 IgG3 IgG4 IgA IgE 
Neutralization + - ++ ++ ++ ++ ++ - 
Opsonisation + - +++ -/+ ++ + + - 
Sensitization for NK 
cell killing 
- - ++ - ++ - - - 
Sensitization of mast 
cells 
- - + - + - - +++ 
Complement 
activation 
+++ - ++ + +++ - + - 
Mean serum 
concentration (mg/ml) 
1.5 0.04 9 3 1 0.5 2.1 3x10-5 
 
All B cells initially express IgM. The rearranged VH-region is literally 
adjacent to the Cµ and Cδ DNA segments and these are transcribed 
together into a single mRNA molecule. IgM and IgD are simply different 
splice variants of the same original mRNA. The Cγ (IgG), Cα (IgA) and 
Cε (IgE) gene segments are further away and are not transcribed in the 
naïve B cell. However, upon activation through stimulation by helper T 
cells and/or cytokines, the enzyme activation-induced deaminase (AID) is 
turned on and switch recombination may occur. Depending on the 
cytokine environment, the rearranged VH-section is brought into proximity 
with Cγ, Cα or Cε and thus the B cell has undergone class-switch. It will 
still have the same specificity but no longer express IgM, instead it will 
produce IgA, IgG or IgE. Class-switch enables the B cells to produce 
antibodies with abilities tailored to the specific needs of the situation, e.g. 
IgE against parasite infection.  
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Resting B cells express their particular antibody on their surface as B cell 
receptors (BCRs). When a B cell encounters its target, it will bind the 
antigen with its BCRs and engulf the pathogen. After degrading the 
antigen, class II MHC-peptide complexes will be displayed on the cell 
surface for recognition by helper T cells. In this sense, B cells are also a 
kind of antigen presenting cell but unlike DCs, they may only present the 
antigen that they specifically recognize. When the B cell encounters a 
helper T cell that recognizes the peptide fragment displayed on the MHC 
class II, it activates the T cell which in turn activates the B cell through 
cytokines and the CD40 ligand. After receiving the “green light” from the 
helper T cell, the B cell undergoes proliferation, class-switch and 
differentiation. The progeny of this naïve B cell may differentiate into 
antibody factories (plasma cells) or memory cells.  
 
Repeated or prolonged exposure to an antigen initiates a process dubbed 
affinity maturation. During the rapid proliferation in the germinal centers 
of lymphoid follicles, the rearranged VH and VL genes of B cells are 
subjected to a high frequency of random point mutations by a process 
involving activation-induced deaminase (AID). This somatic 
hypermutation among the proliferating B cells results in a multitude of 
variants of the initial antibody. All these variants compete for binding to 
antigen displayed by follicular dendritic cells. The B cells carrying BCRs 
with the highest affinity succeed in binding while other B cells die by 
apoptosis. The mutations are randomly introduced but because of the 
evolutionary pressure to produce higher affinity antibodies, the successful 
surviving B cells tend to have accumulated good mutations in the CDR-
regions. The mutations also tend to be of the replacement type, i.e. 
mutations that cause an actual change in the polypeptide sequence. Silent 
mutations are defined as mutations that cause no change in the translated 
protein, e.g. nothing happens if the codon TCC is mutated to TCT since 
both code for the amino acid Serine. By convention, a ratio of 
Replacement to Silent mutations greater than 2.9 is indicative of affinity 
maturation (Shlomchik, Marshak-Rothstein et al. 1987).  
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Sometimes, B cells may initiate immune responses without helper T cells. 
Polysaccharides and lipids can sometimes elicit antibody responses 
without helper T cells. These responses have thus been termed T-
independent. In the case of bacterial polysaccharides, it is believed that 
their polymeric structure is able to crosslink a large number of BCRs and 
thus induce a strong activation signal in a B cell, which may then start to 
proliferate and produce IgM antibodies. Recent data has shown that class-
switch and affinity maturation is also possible during this kind of immune 
responses (Ueda, Liao et al. 2007, Herlands, Christensen et al. 2008, 
Yang, Ghosn et al. 2012). However, the subject of T-independent antigens 
in human biology is still poorly understood and the line between this kind 
of antibody responses and that of natural B1 cells is rather blurry. The 
third manuscript of this thesis does shed some light on this issue but much 
more research is needed.  
 
1.1.2.2 Cellular immunity 
The responsibility of the cellular 
immunity is to eradicate 
intracellular microbes, which may 
come from either direct invasion 
of host cells or ingestion by 
phagocytes. Cellular immunity is 
mediated by two types of T 
lymphocytes, helper T cells 
(CD4+) and cytotoxic T cells 
(CD8+), which both express T cell 
antigen receptors (TCRs). TCRs 
are essentially generated by the same recombination mechanisms as seen 
with the BCRs/antibodies and it has been estimated that each individual 
can produce 1016 unique TCRs, recognizing a wide array of peptides. 
TCRs consist of an α-chain and a β-chain, which both participate in 
antigen recognition. Just like heavy and light chains of BCRs/antibodies, 
Figure 4. The basic TCR structure 
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each of the two chains that make up the TCR contain a variable portion 
and a constant portion.  
 
Differences between BCRs/antibodies and TCRs 
 TCRs are membrane-bound proteins that are never secreted 
 TCRs recognize processed peptide fragments of antigens presented 
on MHC class I (cytotoxic T cells) or class II (helper T cells). This 
is different from BCRs/antibodies, which recognize and bind to the 
three-dimensional surface of antigens.  
 B cells mature in the bone marrow whereas T cells undergo their 
maturation process in the thymus. 
 
T lymphocytes circulate through the peripheral lymphoid organs searching 
for foreign protein antigens. These are transported from the portals of 
microbial entry to the lymphoid organs by activated dendritic cells (DCs). 
At the lymph node, the DCs display processed peptides on MHC class II 
molecules for helper T cells. They may also “cross-present” viral antigens 
to cytotoxic T cells on MHC class I from infected host cells that have 
previously been ingested, thus priming cytotoxic T cells which are specific 
for that antigen. Activated cytotoxic T cells proliferate and differentiate 
into killer cells that limit the spread of intracellular pathogens by lysing 
infected host cells that display viral peptides on their MHC class I.  
 
MHC class I and II 
 MHC class II molecules are used by antigen presenting cells (APCs) 
to display peptide fragments from ingested and degraded antigens. 
These are recognized by helper T cells. 
 MHC class I molecules are present on all cells and display peptide 
fragments from all proteins that are being translated inside the cell. 
Viruses utilize the host cell’s ribosomes to produce viral proteins 
and infected cells will thus display viral peptides on their MHC 
class I, which may be recognized by cytotoxic T cells.   
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 T cells bind to the MHC molecules using their TCRs and an 
additional co-receptor. Helper T cells express CD4 while cytotoxic 
T cells express CD8. Binding to MHC class II requires CD4 and 
binding to MHC class I requires CD8.  
 
A naïve helper T cells that recognizes its specific peptide fragment 
presented by an activated (i.e. also expressing co-stimulators) APC 
becomes itself activated. Depending on the type of stimulation, the naïve T 
cell may differentiate into one of several distinctive types of effector cells. 
The best characterized phenotypes are TH1 and TH2 but other subsets like 
TH17 and TREG are undoubtedly also immensely important. Each subtype 
produces a limited set of cytokines and performs different functions. For 
example, the TH2 subtype which produces IL-4 and IL-5, directs B cells to 
produce anti-parasite IgE and activates eosinophils.  
 
For the pathogenesis of atherosclerosis, the TH1 subtype is generally 
regarded as most important. It secretes the pro-inflammatory IFN-γ which 
under normal circumstances tells phagocytes to eliminate ingested 
microbes and stimulates B cells to produce opsonizing/complement-
recruiting IgG1. However, in the atherosclerotic plaque, IFN-γ exacerbates 
the destructive inflammation.  
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1.2 ATHEROSCLEROSIS – THE UNDERLYING CAUSE OF CVD 
The acute ischemia associated with CVD, e.g. a stroke or myocardial 
infarction, occurs when the blood supply to an organ is blocked by the 
formation of a blood clot (thrombus). However, it is important to 
recognize that the intra-vascular formation of these clots is almost always 
preceded by the rupture of an atherosclerotic plaque.  
 
Atherosclerosis is the progressive accumulation of cholesterol, 
triglycerides, fibrous tissue and inflammatory cells in sections of large- 
and medium-sized arteries throughout the body. It begins early in life as 
have been demonstrated in routine dissections of children where fatty 
streaks are typically observed in the arteries (McGill, McMahan et al. 
2000). These fatty streaks are believed be the precursors of the 
complicated atherosclerotic lesions, which manifest themselves later in 
life.  
 
1.2.1 The pathogenesis of atherosclerosis 
Atherosclerosis has traditionally been viewed as a gradual and passive 
deposition of cholesterol in the artery wall. This understanding was 
primarily derived from clinical observations of patients with familiar 
hypercholesterolemia who suffer from advanced atherosclerosis at an early 
age and then confirmed in the famous Framingham study, which identified 
high cholesterol as one of the risk factors for CVD. Statins were 
specifically developed by the drug industry to lower blood cholesterol and 
this class of drugs has been a huge success, decreasing the number of 
myocardial infarctions by 1/3 according to some estimates (Mihaylova, 
Emberson et al. 2012). However, more recent studies have established that 
one of the main effects of statins is anti-inflammation (Antonopoulos, 
Margaritis et al. 2012) and some experts even argue that this might be the 
true protective effect of statins (Ridker 2013).  
 
The role of low grade inflammation at sites of plaque formation has 
steadily become more recognized over the past two decades and the 
paradigm on atherogenesis has slowly shifted from mainly emphasizing 
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lipids towards a holistic understanding that encompasses the complex 
interplay between lipids, oxidative stress and immune cells (Libby, 
Lichtman et al. 2013). The importance of inflammation in atherosclerosis 
is an excellent example of rediscovered knowledge, for already in the 19th 
century Carl von Rokitansky and later Rudolf Virchow had discovered that 
there was inflammation in the atherosclerotic plaques (Libby 2012).  
 
Figure 5. Schematic anatomy of an arterial wall containing a plaque. 
 
Atherosclerosis development is believed to be initiated when circulating 
low density lipoproteins (LDL) infiltrates the intima layer of the artery 
wall, either through passive diffusion or active transportation by 
endothelial cells (von Eckardstein and Rohrer 2009). The LDL particles 
are trapped in this interstitial space and may be chemically modified by 
enzymes and/or reactive oxygen species (Berliner and Heinecke 1996). 
Oxidized LDL (oxLDL) contains many pro-inflammatory substances, 
including lysophosphatidylcholine (LPC) and lipids that mimic platelet 
activating factor (PAF). These compounds activate the endothelial cells, 
which start to express adhesion molecules on their surfaces and secrete 
chemo-attractants that facilitate the infiltration of leukocytes (primarily 
monocytes and lymphocytes) into the intima part of the arterial wall 
(Eriksson, Xie et al. 2001). Once in place, the monocytes differentiate into 
macrophages and start to engulf modified lipoproteins through their 
scavenger receptors. The result is the formation of lipid-laden foam cells 
which are characteristic for atherosclerosis (Hansson and Jonasson 2009).  
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Macrophages are the most numerous inflammatory cells in human 
atherosclerosis but both T and B lymphocytes can also be identified, albeit 
at much lower numbers. Though few, the T cells are very important in the 
pathophysiology and Professor Libby at Harvard Medical School has 
likened them to generals leading masses of foot soldiers or conductors 
directing orchestras (Libby 2012). The antigens to which the T cells react 
are believed to be modified low density lipoproteins and heat shock 
proteins (Xu, Dietrich et al. 1992, Holvoet and Collen 1998). Besides the 
pro-inflammatory TH1 cells that secrete IFN-γ, there are also regulatory T 
cells (TREG) which ameliorate atherosclerosis by producing transforming 
growth factor-β and in some cases IL-10. The balance between TH1 and 
TREG cells is believed to be of vital importance to the stability of the 
atherosclerotic lesions (Ait-Oufella, Salomon et al. 2006). The net effect of 
B cells in atherosclerosis development is currently unsettled. While some 
studies have shown that B cell depletion with anti-CD20 antibody 
decreases lesion size in mice (Ait-Oufella, Herbin et al. 2010), it is also 
well known that natural antibodies (including anti-PC) are beneficial in 
experimental models (Binder, Shaw et al. 2005).  
 
While most scientists in the field believe the chronic inflammation 
associated with atherosclerosis is caused by modified lipoproteins, there 
are those who have proposed that the inflammation is a reaction to certain 
micro-organisms. The most commonly mentioned pathogens are 
Chlamydia pneumonie, Porphyromonas gingivalis, Aggregatibacter 
actinomycetemcomitans and cytomegalovirus which have all been 
detected in atherosclerotic plaques (Rosenfeld and Campbell 2011).  A 
problem for this infection hypothesis is that treatment studies with 
antibiotics have so far failed to deliver results. While some of these 
micro-organisms like the intracellular bacteria Chlamydia pneumonie 
might be difficult to treat, it is possible that their presence in plaque could 
be the result of a secondary infection. Several of these suggested bacteria, 
e.g. Porphyromonas gingivalis, are dental pathogens. While the link 
between poor dental status and cardiovascular disease has been known 
for a long time, it has been difficult to study the contribution of these 
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pathogens to CVD in isolation since poor dental is associated with a 
multitude of confounding factors. However, the American Heart 
Association has recently published a document stating that there is an 
independent correlation between dental infections and CVD (Lockhart, 
Bolger et al. 2012). An interesting twist to this story is the finding that 
anti-PC antibodies, which we have proposed to be protective against 
CVD, are in fact induced by many bacteria, including dental pathogens. 
Many oral bacteria carry PC groups on the surface and induce robust 
anti-PC responses which are almost exclusively of the IgG2 isotype 
(Schenkein, Gunsolley et al. 1999).  
 
Atherosclerotic plaques are not randomly distributed throughout the 
arterial tree as they are often located at bifurcations and curvatures. The 
shear stress on endothelial cells which is exerted by blood flow has a 
profound effect on cytoskeletal arrangement, leukocyte adhesion, 
lipoprotein permeability and production of vasoactive compounds like 
nitric oxide (Cunningham and Gotlieb 2005). The laminar shear stress at 
straight sections of the arterial tree is protective while the chaotic 
oscillatory flow pattern of swirls created at bifurcations predisposes plaque 
formation. Besides highlighting the importance of shear stress, this also 
underlines the importance of the endothelial cells in the atherosclerotic 
process.  
 
1.2.2 Plaque rupture and Atherothrombosis 
Besides being invaded by leukocytes from the circulation, the 
atherosclerotic plaque is also infiltrated by smooth muscle cells (SMC) 
from the neighboring tunica media layer of the arterial wall and/or 
circulating SMC precursors (Caplice, Bunch et al. 2003). These SMC are 
the source of most of the interstitial collagen that lend strength to the 
fibrous cap that covers the necrotic lipid core of the plaque (Schwartz, 
Virmani et al. 2000). This mass of connective tissue creates bulk, which 
might obstructs blood flow and cause insufficient oxygen supply to the 
myocardium during moments of increased cardiac demand, e.g. climbing 
stairs. However, clinicians have come to recognize that bulky plaques are 
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stable as long as they have a low degree of inflammation (Glagov, 
Weisenberg et al. 1987). The plaques which are prone to rupture are 
characterized by heightened inflammation (Finn, Nakano et al. 2010). The 
core of atherosclerotic plaques contain hefty amounts of pro-coagulants 
like Tissue Factor (Mach, Schonbeck et al. 1997) and even a slight rift of 
the fibrous cap will generate thrombi, which may occlude the artery and 
trigger acute tissue ischemia. The pro-inflammatory environment of 
vulnerable plaques is simmering with cytokines that promotes SMC 
apoptosis and stimulates macrophages to produce matrix 
metalloproteinases (Galis, Sukhova et al. 1994). The decreased production 
of collagen in combination with induction of degrading enzymes 
jeopardizes the biomechanical stability of the fibrous cap that covers the 
plaque, which predisposes rupture (Thim, Hagensen et al. 2008).  
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1.3 ANTIBODIES AGAINST THE PHOSPHORYLCHOLINE EPITOPE 
During the early days of immunology research, the only source of 
monoclonal antibodies was murine myeloma cell lines. The clones were 
given names such as TEPC-15 and M167 and their antibodies were subject 
to intense study. Sometime in the 1960s, it was discovered that the 
antibodies of these cell lines were reactive against small molecules called 
haptens and in the case of M167 and TEPC-15 among others, this hapten 
was found to be phosphorylcholine (PC) (Leon and Young 1971). PC was 
very a hot research topic in the 1970s and 80s as it was considered a model 
for humoral immunity (Early, Huang et al. 1980). There are plenty of 
publications from this time period that report different aspects of PC-
reactive antibody clones. Much of what is today considered basic 
immunological facts, such as somatic hypermutation and class-switching 
were validated in these early PC-studies which many times were published 
in top journals such as Nature and Cell (Crews, Griffin et al. 1981, 
Gearhart, Johnson et al. 1981). 
 
The main target of these PC-antibodies were hypothesized to be bacterial 
polysaccharides for PC was known to be an integral part of many bacteria, 
including some prominent human pathogens such as Streptococcus 
pneumonie, Neisseria meningitis and even the troublesome Pseudomonas 
aeruginosa. This theory was cemented by experiments showing that 
passive immunization with anti-PC could save fatally infected BALB/c 
mice from a certain death (Yother, Forman et al. 1982). The importance of 
the PC-epitope for infectious defense can be further illustrated by C-
Reactive Protein (CRP), which is rapidly produced by the liver in response 
to any infection. This evolutionary conserved acute phase protein is part of 
the innate immune system and aids phagocytosis/clearance by binding to 
PC-epitopes on microorganisms (Mold, Nakayama et al. 1981). In the 
clinic, CRP is the single most important laboratory test for identifying 
patients with serious infections and almost every patient who seeks 
medical attention in an industrialized country has their CRP checked.   
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Just like CRP, anti-PC antibodies are also evolutionarily conserved and 
can be found across many species. Most basic research on the biology of 
anti-PC has been done in murine models where these antibodies are 
believed to be produced by natural CD5+ B1 cells, independent of external 
antigen stimuli. This theory stems from a study that detected TEPC-15+ B 
cells in the spleen of germ free mice (Sigal, Gearhart et al. 1975). It has 
been shown that the mouse anti-PC repertoire is heavily dependent on one 
IGVH-gene (V1) and knocking out this one gene, greatly impairs the 
ability of the mice to produce high affinity anti-PC antibodies, even upon 
vaccination (Mi, Zhou et al. 2000). The absolute majority of publications 
in the field of anti-PC have used mouse models and our present 
understanding of the human antibody response to PC is based on 
extrapolations on from mouse data. It has been a long-standing goal of the 
Frostegård laboratory to bridge this knowledge divide and elucidate the 
underlying biology of human anti-PC antibodies, particularly in relation to 
cardiovascular disease.  
 
Interesting factoids on human anti-PC biology from the Frostegård lab. 
 Women have significantly higher levels than men (Su, Georgiades 
et al. 2006).  
 The anti-PC titer decreases slowly with age (Fiskesund, Su et al. 
2012).  
 Treating rheumatoid arthritis patients with anti-TNF therapy leads 
to decreased inflammation and increasing levels of anti-PC IgM 
(Ajeganova, Fiskesund et al. 2011).  
 However, treating rheumatoid arthritis with anti-CD20 (rituximab) 
lowers anti-PC IgM levels slightly but significantly over 12 months 
(Ajeganova, Fiskesund et al. 2011).  
 Following a gluten free vegan diet increases anti-PC IgM among 
rheumatoid arthritis patients (Elkan, Sjoberg et al. 2008). 
 People living a traditional life, unaffected by Western lifestyle, in 
the island of Kitava (New Guinea) have significantly higher titers of 
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anti-PC IgM than a Swedish control population. This is particularly 
interesting because rheumatologic and cardiovascular diseases are 
unheard of on this island and it is not because people die young. If 
the Kitavans survive childhood, they live till old age. Professor 
Frostegård has hypothesized that diet is playing a role in 
maintaining high anti-PC levels among Kitavans but also exposure 
to microorganisms bearing PC-epitopes, including nematodes and 
parasites (Frostegard, Tao et al. 2007).  
 New born infants lack anti-PC antibodies (unpublished data). This 
has also been reported by the Witztum group in San Diego (Chou, 
Fogelstrand et al. 2009). 
 
As previously alluded to, anti-PC antibodies are ubiquitous in human 
serum and among the almost 10 000 people whose sera have been 
analyzed in the Frostegård laboratory, only one individual has been found 
to lack anti-PC IgM (unpublished data). Though everybody has them, the 
level of anti-PC in sera may differ 100-fold between individuals. On 
average, a human serum contains 320 µg/ml of anti-PC IgG and 110 µg/ml 
of anti-PC IgM (Nishinarita, Sawada et al. 1990). For IgM, that 
corresponds to ~7.3% of the total circulating IgM pool which may seem 
unreasonably high. However, this is something that we have been able to 
confirm during anti-PC IgM extraction experiments. Starting from one 
bottle containing 25mg of purified human IgM (Sigma-Aldrich), we are 
typically able to isolate >2 mg of anti-PC IgM using affinity 
chromatography.  
 
PC is not only found on invading pathogens, it also happens to be an 
integral component of the body’s most abundant phospholipid, 
phosphatidylcholine (PTC). This phospholipid forms the outer layer of all 
cell membranes and coats the highly hydrophobic lipid core low density 
lipoprotein (LDL). PTC consists of one stable saturated fatty acid and one 
unsaturated fatty acid (Figure 6), which is prone to oxidation under the 
certain conditions. One such circumstance occurs during apoptosis, when 
the cellular anti-oxidation systems (e.g. glutathione) malfunctions and 
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Figure 6. Phosphatidylcholine (PTC) is the most common phospholipid in the body. It 
is structurally very similar to Lysophosphatidylcholine (LPC) and Platelet Activating 
Factor (PAF). All three molecules contain a PC-group.  
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exposes the membrane to reactive oxygen species (ROS). Introduction of 
oxygen atoms into certain PTC molecules of the membrane induces 
conformational changes in the membrane that expose PC-groups, which 
may be targeted by anti-PC antibodies (Shaw, Horkko et al. 2000). It has 
been shown that mouse anti-PC binds to apoptotic cells and can be used in 
flow cytometry to visualize dead/dying cells much like a viability dye 
(Shaw, Horkko et al. 2000). The group of professor Silverman has also 
demonstrated that mouse anti-PC IgM aids in the clearance of apoptotic 
cells (Chen, Park et al. 2009). In normal tissue, the removal of dead/dying 
cells is so efficient that you can rarely see apoptotic cells in histological 
sections. However, sections from advanced atherosclerotic lesions are 
literally littered with dead cells (Tabas 2005) and anti-PC might play an 
important role in helping phagocytes clean up.  
 
Figure 7. Oxidation induces conformational changes in the cell membrane that exposes 
the PC-epitope. 
 
 
Besides being exposed on apoptotic cells, the PC-epitope is also found on 
oxidized low density lipoprotein (Chou, Hartvigsen et al. 2008). This is 
also due to oxidation of PTC, which along with ApoB protein covers the 
hydrophobic core of triglycerides and cholesterol. Foam cells which are 
pathognomonic for atherosclerosis are generated when infiltrating 
macrophages ingest oxLDL using their scavenger receptors (ScRs). CD36 
which is one of the main ScR that is responsible for oxLDL ingestion and 
foam cell generation recognizes the PC-epitope of oxLDL (Boullier, 
Friedman et al. 2005). As one would expect, anti-PC IgM has been shown 
to interfere with this process in vitro by blocking the PC-groups on 
oxidized LDL (de Faire, Su et al. 2010).  
oxidation 
 
anti-PC 
 
 
anti-PC 
oxidized PTC 
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Figure 6 illustrates the structural relationship between the compounds 
PTC, platelet activating factor (PAF) and lysophosphatidylcholine (LPC), 
which all contain the PC-group. As previously discussed, PTC is inert and 
an important structural component of cell membranes, but it can be 
converted into highly pro-inflammatory agents by oxidation (Hazen and 
Chisolm 2002). PAF is produced by many cell types but particularly by 
immune cells in response to danger stimuli. While the compound was 
named after its ability to activate platelets, it is probably more important in 
mediating inflammation. PAF has a relatively short half-life for it is 
quickly inactivated by lipoprotein associated phospholipase A2 (Lp-
PLA2), which converts it into LPC. While less potent than PAF, there are 
many publications on the detrimental effect of LPC in atherosclerosis  
(Matsumoto, Kobayashi et al. 2007).  
 
Oxidation of PTC typically generates PAF-like compounds like ox-PAPC, 
PGPC and notably POVPC, which has been shown to bind and activate the 
PAF-receptor (Pegorier, Stengel et al. 2006). This mechanism has been 
hypothesized to be one of the main pathways for initiation of inflammation 
by oxLDL in the arterial wall (Libby 2006). Interestingly, our laboratory 
has reported that anti-PC IgG can neutralize the pro-inflammatory effect of 
PAF on endothelial cells (Su, Hua et al. 2008). PAF-like lipids are like 
PAF, hydrolyzed by Lp-PLA2 into LPC which is one of the main 
components of oxLDL (Matsumoto, Kobayashi et al. 2007). 
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1.4 ANTI-PC AS RISK MARKER/FACTOR FOR CVD 
Examining the risk factors behind a disease provides clues to its 
pathogenesis as well as important information that can be used to derive 
strategies for prediction, prevention and treatment. The distinction between 
risk markers versus risk factors is an important one. Risk factors are by 
definition causal while risk markers are indicators of disease processes and 
may or may not be causal (Vasan 2006).  
 
The town of Framingham in Massachusetts was selected in the 1940s by 
US researchers for a large epidemiological study on biological and 
environmental factors associated with CVD. The subsequent publications 
were among the most important scientific reports in the field of 
epidemiology and the results have had wide-reaching implications for the 
global population. Almost everybody in the industrialized world knows 
about the detrimental effects of Smoking, Physical inactivity, Obesity, 
Family history of CVD, Hypercholesterolemia and Hypertension. Together 
with Diabetes, Old age and Male gender, these attributes represent the 
traditional risk factors of CVD, which are routinely used in the clinic to 
stratify cardiovascular risk. This knowledge forms the backbone of 
modern preventive care.  
 
The traditional risk factors are strongly associated with atherosclerotic 
disease and can explain 75% to 90% of all events (Greenland, Knoll et al. 
2003, McGill, McMahan et al. 2008). The chance of getting CVD is low if 
one does not have any of the aforementioned risk factors (Lloyd-Jones, 
Leip et al. 2006). Although the traditional risk factors have proven to be 
very valuable, complacency is a mentality unknown to scientists. There is 
a need for further understanding of the disease in order to identify novel 
targets for treatment. Since the importance of the chronic inflammation 
component of CVD has become increasingly apparent over the last two 
decades, much attention has been given to biomarkers that are related to 
inflammation. High-sensitive CRP levels (Devaraj, Singh et al. 2009) and 
the activity of serum Lp-PLA2 enzyme (Rosenson and Stafforini 2012) 
have both been independently correlated with CVD. In the case of Lp-
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PLA2, inhibitors have been developed that have shown promise in animal 
models (Wilensky, Shi et al. 2008, Wang, Zhang et al. 2011).  
 
Though the study of anti-PC antibodies went out of fashion during the late 
1980s, in recent years, the field has undergone a renaissance. The 
discovery that the classic PC-reactive TEPC-15 clone recognizes oxidation 
specific epitopes (Shaw, Horkko et al. 2000) opened up a whole new 
avenue of investigation. Subsequent research has demonstrated that anti-
PC aids in clearance of apoptotic cells (Chen, Park et al. 2009) and 
prevents the formation of foam cells in atherosclerosis by clearing 
oxidized low density lipoprotein (de Faire, Su et al. 2010).  Murine 
vaccination studies to induce robust humoral PC-responses have likewise 
shown strong beneficial effects on experimental atherosclerosis in vivo 
(Binder, Horkko et al. 2003, Caligiuri, Khallou-Laschet et al. 2007). 
Given this body of evidence, professors Frostegård and de Faire at 
Karolinska Institutet began to advance anti-PC IgM deficiency as a novel 
risk marker for CVD (de Faire and Frostegard 2009). This hypothesis has 
been tested and validated in several large CVD cohorts in Sweden. Low 
serum level of anti-PC IgM has consistently been linked to increased risk 
of CVD. This association is independent of the traditional risk and anti-PC 
IgM as a test might thus identify risk patients that the traditional risk 
factors do not pick up.  
 
Table 3. Summary of the epidemiological studies on anti-PC IgM and CVD. Having a 
low serum level of anti-PC is associated with increased CVD-risk. 
STUDY 
Odds 
Ratio 
95% Confidence Interval 
VIP/MONICA  
(Gronlund, Hallmans et al. 2009) 
1.69 1.09 - 2.54 
Malmö Diet Cancer  
(Sjoberg, Su et al. 2009) 
2.01 1.11 - 3.67 
Castro II  
(Fiskesund, Stegmayr et al. 2010) 
1.62 1.11 - 2.35 
Stockholm 60-year old men 
(de Faire, Su et al. 2010) 
1.96 1.09 - 3.55 
Gothenburg ACS  
(Caidahl, Hartford et al. 2012) 
2.28 1.32 – 3.92 
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2 AIMS OF THE THESIS 
 To study the relationship between anti-PC levels and the incidence 
of stroke in a population-based cohort from northern Sweden. 
 To investigate the properties of anti-PC antibodies belonging to 
different classes/subclasses (IgM, IgA, IgG2 etc). 
 To determine the stability/consistency of serum anti-PC IgM titers 
(within the same individuals) over time period of 4 years.  
 To identify and characterize PC-reactive human B cells and produce 
human anti-PC monoclonal antibodies.   
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3 METHODOLOGICAL CONSIDERATIONS 
All experiments in this thesis were conducted on human serum and cells 
originating from voluntarily donated blood. The studies were approved by 
ethical boards at Karolinska Institutet and Umeå University prior to 
initiation. This section contains detailed descriptions of the methods that 
were used in the experiments. The corresponding papers are referred to 
with roman numerals (I-III). 
 
 
3.1 STUDY GROUPS 
3.1.1 VIP/MONICA cohort (paper I) 
The MONICA project was part of the World Health Organization (WHO) 
initiative to study trends in CVD. Every fourth year, 2000 to 2500 persons 
(25 to 74 years of age) living in two Swedish counties (Norrbotten and 
Västerbotten) were invited to a health examination. Doctors would record 
height, weight, blood pressure, smoking habits, serum cholesterol, and 
lifestyle habits (Stegmayr, Lundberg et al. 2003). Participants were also 
encouraged to donate blood for future research, stored as heparin–plasma 
in the Northern Sweden Medical Research Bank (Lenner, Hallmans et al. 
1991). In paper I, we used data from the Northern Sweden MONICA 
project for the years 1985 through 1999. 
 
VIP is an ongoing project in the Swedish county of Västerbotten. It was 
initiated in 1985 and was originally intended as a health promotion 
program for the population in this county (Västerbotten; ≈250 000 
inhabitants). Every year, all persons reaching the ages of 30, 40, 50, and 60 
are invited to their local health centers for a routine screening. The 
questionnaire for VIP is very similar to the one used in the MONICA 
project. All participants are asked to donate blood samples, which are then 
stored in the above-mentioned biobank. By December 2002, a total of 74 
000 unique people had attended health examinations within the framework 
of the project. 
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The participation rate is 60% for VIP and 77.2% for MONICA. Previous 
publications on nonparticipants have shown that nonparticipants in VIP are 
quite similar to the participants from a socioeconomic standpoint, 
indicating a marginal social selection bias (Weinehall, Hallgren et al. 
1998).  
 
3.1.2 Hypertension cohort (paper II) 
The European Lacidipine Study on Atherosclerosis (ELSA) was a 4-year 
prospective study on hypertension treatment in relation to development of 
atherosclerosis in the carotid artery (Zanchetti, Bond et al. 2002). The 
Swedish branch of this European collaboration consisted of 226 subjects 
who had established hypertension (diastolic pressure >95 mm Hg). During 
the admission process, information on age, gender, blood pressure, weight, 
height, smoking habits and previous medical history was recorded along 
with laboratory values of different parameters including creatinine, fasting 
glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol and 
triglycerides.  From this cohort, we have previously determined that high 
levels of anti-MDA-LDL, anti-oxLDL and anti-PC IgM are protection 
factors for atherosclerosis development (Su, Georgiades et al. 2006). In 
paper II we explore the roles of anti-PC IgG1, IgG2 and IgA, different 
antibody idiotypes as well as the long term stability of anti-PC IgM levels. 
We have also used this cohort to study the predictive power of combining 
anti-PC with anti-MDA-LDL or anti-oxLDL. 
 
3.2 CAROTID ULTRASOUND 
The carotid Intima-Media Thickness (IMT) is often used as a surrogate 
marker for global atherosclerosis (Mancini, Dahlof et al. 2004).  
 
The mean of the maximum Intima-Media Thicknesses (IMT) in the far 
walls of common carotids and bifurcations (CBMmax) was determined by 
B-mode ultrasonography at the time of inclusion, and 4 years afterwards. 
All scans were performed with the Biosound 200 II device (All Imaging 
Systems inc., Irvine CA, USA) and read at the Ultrasound Coordinating 
Center with quality assurance accomplished as reported. The levels of the 
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different anti-PC antibody classes/subclasses at enrollment were evaluated 
with respect to increase or decrease in IMT at the 4-year follow up.  
 
3.3 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
3.3.1 Determination of serum anti-PC levels 
Detection of IgM anti-PC antibodies was performed with an ELISA kit 
from Athera Biotechnologies AB. The assay is based on PCs covalently 
linked to BSA and then coated onto 96-well Nunc Maxisorp microtiter 
plates. The assay was performed in accordance with manufacturer 
recommendations. All readings of results were performed on ELISA 
Multiscan Plus spectrophotometer (Molecular Devices, San Francisco). 
The coefficients of variation for the samples were <7%. 
 
For determination of other immunoglobulin classes, this ELISA-kit was 
modified by switching the secondary antibody. The Athera-kit provides 
anti-human IgM coupled to horse radish peroxidase (HRP). When 
detecting anti-PC IgA, we simply switched to an anti-human IgA HRP 
from Sigma-Aldrich (goat anti-human IgA HRP). The secondary 
antibodies against the IgG subclasses were purchased from Invitrogen. The 
Athera-kit comes with an anti-PC IgM standard curve. For the other 
immunoglobulin classes/subclasses, we devised our own standard curve 
using serial dilutions of donated serum and defined arbitrary units 
(Units/ml). 
 
3.3.2 Determination antibody levels against modified LDL 
LDL was isolated from plasma of healthy donors by sequential 
preparative ultra-centrifugation and oxidized using copper ions (oxLDL) 
or modified with MDA (MDA-LDL). These were then coated on 
microplates, which were later blocked with 20% adult bovine serum in 
PBS (20% ABS-PBS). Diluted serum samples were incubated overnight 
at 4 °C. The presence of specific antibodies in the serum was detected 
using goat anti-human IgG ALP/anti-human IgM ALP in combination 
with substraste (pNPP) and read at 405 nm. 
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3.3.3 Characterization of the fine-specificities 
The binding specificity of human anti-PC IgG1, IgG2, IgM and IgA were 
determined in a competitive ELISA with p-nitrophenylphosphorylcholine 
(NPPC) hapten or phosphorylcholine (PC) hapten in accordance with 
previously published work (Brown, Schiffman et al. 1984). Briefly, 
hapten was mixed with pooled IgA or affinity purified anti-PC from 
pooled IgG/IgM and incubated in the wells of the ELISA microplate. 
Antibodies of each isotype were then detected with the above-mentioned 
class/subclass specific secondary antibodies. 
 
3.3.4 Polyreactivity ELISA 
Besides PC-reactivity, the human anti-PC mAbs that we produced in paper 
III were also screened for reactivity against unspecific antigens as 
previously described (Wardemann, Yurasov et al. 2003). Antibodies were 
classified as polyreactive if they recognized at least two out of three 
analyzed antigens (double-stranded DNA, insulin and LPS). All ELISAs 
were developed with HRP–conjugated goat anti-human IgG (Jackson 
ImmunoResearch) and revealed using the chromogenic substrate 3,3’,5,5’-
tetramethylbenzidine (Bio-Rad). Plates were read at 450 nm with a 
reference of 650 nm. To be considered reactive the results for any given 
antibody had to be confirmed in at least two independent experiments. 
 
3.4 PURIFICATION OF SERUM ANTI-PC IgG AND IgM 
Pooled human IgG (Baxter, Deerfield IL, USA) and IgM (Sigma Aldrich, 
St. Louis MO, USA) was passed over a column containing PC-Sepharose 
(Biosearch technologies, Novato CA, USA). The column was then 
washed with Phosphate Buffered Saline (PBS) pH 7.4 with Tween20 to 
remove non-bound immunoglobulins. These non-anti-PC antibodies were 
collected to be used as control antibodies (flowthrough 
immunoglobulins) in later experiments. The bound PC-specific 
antibodies were then eluted with 0.01 M acetic acid and 
concentrated/buffer exchanged to PBS pH 7.4 using Centricon Plus-70 
centrifugation filter units (Millipore, Billerica MA, USA). 
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3.5 CELL VIABILITY ASSAY 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy 
coats using the standard protocol of Ficoll density gradient 
centrifugation. The freshly produced PBMC were counted and 
resuspended in RPMI 1640 before being seeded into 24-well plates at a 
concentration of 3×106 cells per ml. 
 
L-α-Lysophosphatidylcholine (LPC) from egg yolk (Sigma) was first 
dissolved in ethanol and then further diluted in RPMI 1640 to a working 
stock solution. LPC was added to the cells of each well, either by itself, 
together with purified anti-PC IgM, total IgM or flowthrough IgM. After 
a 18 hour incubation period, cell viability was evaluated with the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. 
Live cells with functioning mitochondria metabolize MTT to formazin, 
which absorbs light at 570 nm. The viability of the cells in each well was 
thus quantified by collecting the insoluble formazin formed in each well, 
dissolving it in DMSO and reading the optical density (OD) at 570 nm. 
 
3.6 BIOCONJUGATION OF PC TO PHYCOERYTHRIN 
Phosphorylcholine hydroxyphenylacetic acid (Biosearch Technologies) 
was mixed with EDC along with sulfo-NHS and the resultant amine-
reactive PC-compound was added to pure phycoerythrin (PE) protein.  
After one hour, the protein-hapten product (PC-PE) was isolated using a 
PD-10 Desalting Column (GE Healthcare).  
  
PC-reactive TEPC-15 IgA from mouse myeloma (Sigma Aldrich) was 
passively adsorbed onto 5µm latex beads (Invitrogen) and subsequently 
blocked with BlockAce (AbD Serotec). The beads were stained with equal 
amounts of either PC-PE or native PE and analyzed on a LSR Fortessa 
flow cytometer (Becton Dickinson) for the purpose of confirming 
successful conjugation of PC to PE.  
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Further validation of the PC-dye was performed by Ig-ELISpot using 
commercial ELISpot-kits (Mabtech) and isolated B cells from buffy coats. 
Individual wells on ELISpot-plates were coated overnight at 4°C with 
either 10µg/ml of PC-BSA (Biosearch Technologies) or anti-IgM 
(provided in the kit) and then blocked with culture medium (RPMI 1640 + 
10% FCS). B cells from four healthy individuals were stained with 
antibodies before being sorted into ELISpot-plates (100-200 cells/well). 
Sorted B cells were allowed to secrete immunoglobulins for 16 hours at 
37°C with 5% CO2. The frequency of spot-generation by PC+ cells sorted 
on PC-BSA surface (nr of true PC-reactive B-cells) was compared to that 
of PC+ cells sorted on anti-Ig surface (total nr of sorted viable B cells) and 
found to be comparable.  
 
3.7 PHENOTYPIC CHARACTERIZATION OF PC-REACTIVE B CELLS  
B cells from 19 healthy individuals were stained with antibodies and 
reagents and analyzed on a LSRFortessa flow cytometer with an 
acquisition target of 3x106 cells. The data was then dissected in FlowJo 
v7.6.5 (TreeStar). Delineation of CD5+ in B cells was done by FMO 
control. Total B cell count was estimated using CD19 BV421 in 
conjunction with CountBright Beads (Invitrogen) according to Becton 
Dickinson’s lyse-no-wash protocol. 
 
3.8 SINGLE B CELL SORTING 
Freshly isolated B cells from ten healthy individuals were kept overnight 
in RPMI 1640 + 10% FCS and sorted the following morning. Total B cells 
were divided into IgG+, naïve, IgM+ memory and CD27+CD43+ subsets 
based on surface markers and subjected to first round of sorting using a 
FACSAria III (Becton Dickinson). PC+ B cells from each subset were 
collected during the 4-way sort was then re-sorted using the same gating 
strategy  and deposited as single cells into 96-well Twintec PCR-plates 
(Eppendorf) containing lysis buffer as previously described (Tiller, Meffre 
et al. 2008). The purity of PC-reactive B cells was typically 67% and 
100% after the first and second rounds of sorting, respectively. 
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3.9 cDNA SYNTHESIS, PCR AMPLIFICATION AND SEQUENCING  
Single cell cDNA was synthesized in the original 96-well PCR plate by 
addition of nucleotides and SuperScript III RT (Invitrogen). Individual 
IgH (γ or µ) and IgL chain (κ or λ) genes rearrangements were amplified 
independently, using the cDNA as template, by two successive rounds of 
PCR (50 cycles each) as previously described (Tiller, Meffre et al. 2008). 
The PCR-products were then sequenced using BigDye 3.1 terminator 
chemistry (Applied Biosystems) and read in an ABI 3730 instrument 
(Applied Biosystems). Light chains were sequenced once and heavy 
chains were sequenced twice (once from 3’-end and once from 5’-end) for 
highest fidelity.  
  
3.10  IMMUNOGLOBULIN GENE SEQUENCE ANALYSIS 
Ig gene usage and somatic hypermutations were analyzed by IgBLAST 
(http://www.ncbi.nlm.nih.gov/igblast/). Replacement (R) and silent (S) 
mutations frequencies in framework regions (FWRs) and CDRs were 
calculated for each region based on the absolute number of nucleotides in 
all analyzed sequences as defined by IgBLAST. IgG isotype subclasses 
were determined using the international IMmunoGeneTics information 
system (http://imgt.cines.fr). 
 
The heavy-chain sequences were translated and the HCDR3 regions were 
aligned by means of the ClustalW peptide alignment algorithm. Clustered 
antibodies were considered to be of the related if their associated light 
chains utilized the same Vλ/κ and J λ/κ genes. Phylogenetic mapping of 
clonally related antibodies from the same donor was performed by 
counting shared and unique mutations in relation to the corresponding 
germline IGHV-gene.  
 
3.11  CLONING AND ANTIBODY PRODUCTION 
Restriction sites for expression vector cloning were introduced by using 
gene-specific primers and first PCR products as template as previously 
described (Wardemann, Yurasov et al. 2003, Tiller, Meffre et al. 2008). 
The digested PCR products from each single cell were cloned into 
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expression vectors containing human Igγ1, Igκ, or Igλ constant regions 
(Wardemann, Yurasov et al. 2003, Tiller, Meffre et al. 2008). Ligation 
reactions were performed using the quick ligase kit (NEB) according to the 
manufacturer's instructions. Expression vectors containing IgH and the 
corresponding IgL genes were isolated from transformed-DH5alpha 
bacteria (Invitrogen) using plasmid DNA purification kits 
(NucleoSpin®Plasmid, Macherey-Nagel) and then sequenced to confirm 
consistency with the original PCR products. 
 
Antibodies were produced by transient co-transfection of exponentially 
growing 293 human embryonic kidney fibroblasts using PEI-Max 
(Polysciences). Supernatants were collected after seven days of culture, 
and antibodies were purified by binding to protein G–Sepharose 4FF (GE 
Healtcare). Expression of antibodies consisting of both heavy and light 
chains, as well as the protein purity, was verified by SDS-polyacrylamide 
gel electrophoresis. 
 
3.12  SURFACE PLASMON RESONANCE 
In order to determine the affinity of ten human mAbs to PC, we performed 
surface plasmon resonance (SPR) analyses on a Biacore X100 instrument 
(GE Healthcare). The selection process of mAbs for the SPR analysis was 
conducted to generate a representative group of mAbs from different B 
cell subsets, using different Ig-genes and include both κ and λ clones. 
Monoclonal human antibodies were covalently bound at 10µg/ml to CM7 
sensor chips through amine coupling in accordance with the 
manufacturer´s instructions. Once the antibodies had been immobilized, 13 
different concentrations (0-200 µM) of free PC-hapten in solution were 
sequentially injected at a flow rate of 30 µl/min. Data was collected using 
multi-cycle kinetics and the bindings were analyzed using the Biacore 
X100 Evaluation software, version 2.0 (GE Healthcare) and fitted with a 
mathematical steady state affinity model. 
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3.13  STATISTICS 
Serum antibody levels were dichotomized or determined as continuous 
variables as indicated. We calculated percentiles based on data from the 
whole study group. Wilcoxon rank sum tests or t tests were applied 
depending on the distribution of data. The association between antibodies 
and incident stroke were determined by conditional logistic regression 
models with calculation of odds ratios and 95% CIs. Age, gender, and 
geography were matched for by the design of the study (paper I). The 
association between antibodies and the progression of atherosclerosis over 
a 4-year period were determined by estimating increases in IMT (yes or 
no) using conditional logistic regression analysis (paper II). Adjustments 
were made for possible confounders including smoking habits, body mass 
index, diabetes, hypercholesterolemia (serum cholesterol ≥5.0 mmol/L), 
and hypertension (≥140/90 mm Hg systolic/diastolic) (paper I and II). A 
two-tailed P value <0.05 was considered significant. SAS was used for 
statistical analyses of epidemiological data (release 9.1; SAS Institute 
Inc.). 
 
Student’s t-test was used to test statistical differences in the in vitro 
experiments. The r2-value and statistical significance of the correlation 
between serum anti-PC IgM and number of PC+CD27+CD43+ B cells in 
blood was calculated according Pearson. The significance of IgG-subclass 
distributions was determined through Fischer’s exact test. These analyses 
were performed in GraphPad Prism v6.02 and R v2.13.2. 
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4 RESULTS AND DISCUSSION 
 
4.1 ANTI-PC IGM AND RISK OF STROKE 
Paper I is a classic nested case-control study, which is based on a cohort 
that was created by our co-authors in Umeå. They had access to blood 
samples and life-style data from the huge MONICA and VIP initiatives 
(see methodology section). Using the Swedish stroke registry, they 
identified 227 people who had participated in the health checks and later 
developed a first-time stroke. They also selected 455 age- and sex-
matched controls from the same MONICA/VIP material. 
 
We measured the anti-PC IgM levels in this cohort and reported that the 
median levels of IgM anti-PC levels did not differ significantly between 
stroke cases and controls. However, when analyzing relative risks for 
stroke at various cut-off levels for anti-PC levels, significance was 
reached at the 30th percentile (multivariately adjusted odds ratio (OR) 
1.62; CI, 1.11 to 2.35). This association was independent of and 
unaffected by other risk factors, including smoking habits, body mass 
index, diabetes, hypercholesterolemia, and hypertension. This finding 
confirms and extends our previous reports regarding an inverse 
relationship between anti-PC and atherosclerosis or CVD.  
 
When gender-specific analyses were performed, significant relative risks 
were seen for women at levels of IgM anti-PC <52 U/mL, corresponding 
to the median, for both crude data and after multivariate adjustments (OR 
1.92; CI, 1.13 to 3.28). Although already significant below the median, 
the relationship gets even more pronounced in the lower percentiles (OR 
2.65; CI 1.41 to 4.95). To our disappointment, no association was seen 
among the men in this study.  
 
In a subgroup analysis of our previously published Malmö Diet Cancer 
study, low anti-PC levels came out as a significant predictor for ischemic 
stroke, with a relative risk as high as 4 among men (Sjoberg, Su et al. 
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2009). However, there were too few females in that study to provide 
reliable data on women. The results of the subgroup analysis in the 
Malmö Diet Cancer study differ from the present study because here we 
only noted low anti-PC to be related to an increased stroke risk among 
women, whereas in the previous report, this association was only 
significant among men. Our finding here was therefore a bit unexpected.  
 
There could be several explanations for this discrepancy (power issues, 
differences in population structure, age distributions, etc). First, in the 
present study, stroke was the primary and only endpoint. Second, in the 
Malmö study, the number of women was relatively low, providing 
analyses with low power. Further on, in addition to the geographical, 
genetic, socioeconomic, and dietary differences between the cohorts, the 
most striking difference is the age structures of the two studies. The 
subjects in the current study are on average of 5 years younger than those 
included in the Malmö Diet Cancer study, and we have a greater spread 
of age in the current study, with some stroke cases occurring at 30 years 
of age. The average age at stroke incidence in this cohort was just above 
60 years, which is relatively young in the context of stroke. 
 
Both the current study and the Malmö Diet Cancer study are based on 
post hoc analyses. This is a limitation to both studies and the possibility 
of chance findings can never be completely ruled out. There might also, 
as always, be unknown confounders. However, of note is that adjustment 
for available confounders does not weaken our results. Future studies on 
various populations are warranted to reliably and consistently estimate 
risk associations. 
 
Persons who developed stroke and incidentally had atrial fibrillation were 
included among stroke cases because the study design does not make 
distinctions between subtypes of stroke. This is partly because it is 
sometimes hard to correctly identify cardioembolic stroke cases and 
partly because the majority (85%) of ischemic strokes are attributable to 
atherosclerosis anyway (Warlow 1998). The number of possible atrial 
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fibrillation–related strokes was most likely not very common because our 
stroke cases were comparably young and atrial fibrillation is rather 
uncommon in this age group. 
 
The mechanisms by which anti-PC could protect against stroke might be 
related to the anti-inflammatory properties of anti-PC, inhibiting the 
inflammatory effects of PC-containing inflammatory phospholipids 
including platelet-activating factor. 
  
In conclusion, we reported in this study that anti-PC IgM levels below 
the 30th percentile could be used to predict increased risk for stroke in a 
population-based study from Northern Sweden. In subgroup analyses, 
this association was only present among women. The findings presented 
here may potentially open up for novel immunotherapy regimens against 
atherosclerosis and stroke or other forms of CVD either through passive 
transfer of anti-PC antibodies or active immunization using PC as an 
antigen. However, additional large-scale studies are needed to determine 
the exact role of anti-PC in women and men. 
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4.2 ANTI-PC SUBCLASSES AND IMT-PROGRESSION 
The European Lacidipine Study on Atherosclerosis (ELSA) was a 4-year 
prospective study on hypertension treatment in relation to development 
of atherosclerosis in the carotid artery (Zanchetti, Bond et al. 2002). 
From this cohort, we had previously determined that high levels of anti-
oxLDL IgM, anti-PC IgM (but not IgG) and antibodies against  
malonyldialdehyde modified LDL (anti-MDA-LDL) are protection 
markers for atherosclerosis development (Su, Georgiades et al. 2006). In 
the present study we wanted to go further and explore the roles of anti-
PC IgG1, IgG2 and IgA as well as the long term stability of anti-PC IgM 
levels.  
 
Measurable levels of anti-PC IgG1 and IgG2 were found in most subjects 
whilst levels of IgG3 and IgG4 were generally undetectable. Thus only 
anti-PC IgG1 and IgG2 were included in the subsequent investigation. We 
found no correlation between anti-PC IgG2 and IMT-changes (OR 0.96, 
CI 0.38 to 2.43, p=0.94 above the 90th percentile). However, a high level 
of the IgG1 subclass at baseline was strongly predictive of no increase in 
IMT after four years (OR 0.22, CI 0.08 to 0.60, p<0.01 above the 90th 
percentile). Testing serum for anti-PC IgA showed that subjects with low 
levels of anti-PC IgA had increased risk for IMT-progression (OR 2.46, CI 
1.22 to 4.99, p=0.01 below the 25th percentile). A protective effect at high 
levels was not seen for anti-PC IgA. 
 
Low levels of anti-PC IgM has consistently been correlated with CVD in 
previous studies (de Faire, Su et al. 2009, Gronlund, Hallmans et al. 
2009, Sjoberg, Su et al. 2009, Fiskesund, Stegmayr et al. 2010). This 
study introduces two new biomarkers, anti-PC IgG1 and IgA. Spearman 
rank correlation coefficients show that levels of anti-PC IgM, IgA and 
IgG1 are all closely associated. This implies that it is only necessary to 
measure one antibody class since measuring more classes would be 
redundant. Given that all previous publications have used anti-PC IgM 
and the availability of a ready-to-use ELISA kit, it is wise to continue the 
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use anti-PC IgM for risk assessments. However, the role of anti-PC IgA 
deserves further study due to its intricate connection with gut immunity. 
 
4.3 FINE SPECIFICITY DIFFERENCES AMONG THE ANTI-PC ISOTYPES 
Anti-PC antibodies are subdivided into two populations based on their 
affinity for phosphorylcholine (PC) and p-nitrophenylphosphorylcholine 
(NPPC) (Brown, Schiffman et al. 1984). The fine specificity profiles of 
anti-PC IgM, IgA, IgG (total), IgG1 and IgG2 were determined in pooled 
fractions of immunoglobulins to minimize the impact of individual 
variation. Human anti-PC IgM and IgA were found to be exclusively 
Group I (similar to the murine T-15 clone). The IgG fraction, however, 
was determined to contain both Group I and Group II antibodies. 
Detailed examination with subclass specific antibodies revealed a 
significant discrepancy between anti-PC IgG1 and IgG2 with regard to 
specificity. Whereas the IgG1 pool was found to be mostly Group I, the 
IgG2 pool was clearly made up of Group II anti-PC antibodies. 
 
Patients suffering from periodontal diseases have an elevated risk for 
CVD (Blaizot, Vergnes et al. 2009) even though they develop high titers 
of anti-PC IgG2 (Schenkein, Gunsolley et al. 1999). This finding might 
seem to contradict the “house-keeping” hypothesis, in which high levels 
of anti-PC antibodies are supposed to prevent atherosclerosis and CVD. 
However, our new data provides an explanation. We have demonstrated 
that only antibodies of the Group I idiotype are associated with decreased 
atherosclerosis progression. The level of anti-PC IgG2 (Group II) was not 
associated with IMT-changes at all (p=0.94). Given that IgG2 antibodies 
are used to counter carbohydrate antigens (Scott, Shackelford et al. 
1988), it is likely that anti-PC IgG2 is produced in response to PC-
bearing bacteria. Human anti-PC IgG2 has, in fact, been implicated as a 
bactericidal agent against Streptococcus pneumonie and  Haemophilus 
influenza (Goldenberg, McCool et al. 2004). 
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4.4 COMPOSITE MARKERS IMPROVES THE RISK ASSESSMENT  
Combining data on anti-PC IgM with anti-MDA-LDL strengthened the 
negative association with IMT-progression at levels above the 90th 
percentile for both antibodies (OR 0.10, CI 0.01 to 0.85, p < 0.05). This 
improved predictive value was also noted between anti-PC IgM and anti-
oxLDL IgM at levels above the 90th percentile for both antibodies (OR 
0.12, CI 0.03 to 0.42, p < 0.05). These combinations are stronger than 
each of the individual markers by themselves. Anti-MDA-LDL like anti-
PC is a natural antibody that has been widely studied in the context of 
CVD (Chou, Fogelstrand et al. 2009). The finding that the two 
antibodies can act in synergy opens up exciting avenues related to in vitro 
experiments as well as immunization strategies involving induction of 
both anti-PC and anti-MDA-LDL. Although combining two different 
antibodies produces impressive odds ratios (OR), the best OR is obtained 
by only looking at the very highest levels (top 5th percentile) of anti-PC 
IgM alone (OR is 0.05,  CI 0.006 to 0.40, p < 0.001). Among the twelve 
study participants in the top 5th percentile, only one had IMT-
progression after four years (8.3%). For those below the 95th percentile, 
the incidence of IMT-progression was 137 cases in 214 subjects (64%). 
While the limited number of individuals in this group urges caution, it is 
still a striking finding. 
 
 
4.5 ANTI-PC INHIBITS LPC INDUCED CYTOTOXICITY ON CELLS 
Both purified anti-PC IgM and total IgM was able to inhibit LPC-induced 
cytotoxicity (p<0.05) in human immune cells. The effect seen with the 
flowthrough IgM fraction (largely depleted of anti-PC IgM) was not 
significant. 
 
We have previously demonstrated that anti-PC can inhibit the formation 
of foam cells (de Faire, Su et al. 2010) and neutralize the pro-
inflammatory effect of PAF (Su, Hua et al. 2008). In this study, we have 
identified an additional mechanism through which anti-PC could confer 
protection against CVD and atherosclerosis, where dead cells are 
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abundant. Apoptosis is known to weaken advanced atherosclerotic 
plaques (Seimon and Tabas 2009) and inhibiting LPC-induced cell death 
could be very important in stabilizing plaques that might otherwise 
rupture, especially considering the richness of LPC in plaques (Portman 
and Aexander 1969). 
 
4.6 SERUM LEVEL OF ANTI-PC IgM IS DOES NOT CHANGE 
The level of anti-PC IgM was measured in serum samples taken at two 
time points, four years apart (admission and follow-up). During this time 
period, levels of anti-PC IgM changed remarkably little in most patients. 
The Spearman rank correlation coefficient between the samples taken 4 
years apart was determined to be 0.92 with a p-value of less than 0.0001. 
 
Long term stability is important quality for a biomarker that makes claim 
to predict atherosclerosis progression and cardiovascular events many 
years in the future. A previous study indicated that anti-PC IgM was 
constant over a period of many weeks (Padilla, Ciurana et al. 2004). 
Here we have, for the first time, shown that the levels are steady over a 
four year period. 
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4.7 PC-REACTIVE B CELLS ARE ABUNDANT IN BLOOD 
In order to isolate PC-reactive B cells, we conjugated PC-hapten onto 
phycoerythrin (PE) for flow-cytometric identification of B cells carrying 
PC-reactive surface immunoglobulin.  The brightly fluorescent end-
product, PC-PE was validated for specificity and then used in combination 
with a panel of monoclonal antibodies to divide CD19+ B cells into four 
subsets, [1] IgM+ memory, [2] IgG-switched, [3] naïve B cells and [4] 
CD27+CD43+ B cells. Each B cell subset was then further subdivided into 
PC-reactive and PC-negative B cells. Single PC-reactive B cells from each 
subset were isolated following two successive rounds of sorting.  
 
PC-reactive B cells were readily identifiable in all examined B cell subsets 
and found to be particularly enriched in the IgM+ memory population, 
which is consistent with the view that this subset is important for 
combating carbohydrate and lipid antigens (Weller, Braun et al. 2004). 
While PC-reactive B cells in the CD27+CD43+ population were the hardest 
to come by (approximately 10 cells per million B cells), a large proportion 
of these cells were spontaneously secreting IgM. The relative number of 
these CD27+CD43+ B cells as identified by flow-cytometry was 
significantly correlated to the serum level of anti-PC IgM (r2=0.42; 
p=0.0025).  
 
Regarding the nature of the CD27+CD43+ population, which has recently 
been described as human equivalents of mouse B1 cells (Griffin, Holodick 
et al. 2011), we could confirm that they do spontaneously secrete IgM. 
However, many of our subsequent findings contradict the innate nature of 
these cells. Antibodies cloned from CD27+CD43+ B cells were as mutated 
as those from class-switched B cells. Furthermore, a large number of PC-
reactive cells in the CD27+CD43+ population were found to be clonally 
related to cells from other memory populations as visualized by 
phylogenetic trees. Although CD27+CD43+ B cells may not be innate 
lymphocytes, they definitely exist and probably execute important tasks. 
Here, we have shown that the number of PC-reactive CD27+CD43+ is 
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significantly correlated with serum anti-PC IgM, suggesting that these are 
key antibody-secreting cells.  
 
In mice, CD5 is an established marker for natural B1 cells, including 
murine PC+ B cells (Griffin, Holodick et al. 2011). In order to assess 
whether CD5 is also preferentially expressed on human PC+ B cells, we 
analyzed CD5-expression among human B cells in ten individuals. We 
here report that approximately 8% of CD27+ memory B cells and 30% of 
naïve B cells were CD5+, however, CD5 was equally expressed on PC+ 
and PC- B cells. These data show that CD5 is not a useful marker for PC+ 
B cells in man. 
 
4.8 THE HUMAN ANTI-PC REPERTOIRE IS DIVERSE AND MUTATED 
We sorted single PC-reactive B cells from ten healthy individuals in order 
to characterize the anti-PC repertoire in a healthy population. Complete 
sequencing data was obtained from 1388 PC-reactive cells and after 
analysis, we found that the human anti-PC specificity can be conferred by 
a wide array of immunoglobulin gene combinations. Although the anti-PC 
repertoire is arguably skewed  towards certain families of Ig-genes 
(IGHV3, IGKV3 and IGKV4), it still does not change the narrative of a 
broad immune-response towards this small epitope.  
 
Although PC-reactive B cells likely operate with minimal T-cell help, the 
antibodies showed significant levels of mutations. Granted that this seems 
counterintuitive, recent publications have unequivocally demonstrated that 
affinity maturation and class-switching can occur without T-cells, albeit 
the process is more cumbersome (Ueda, Liao et al. 2007, Herlands, 
Christensen et al. 2008, Aranburu, Ceccarelli et al. 2010, Yang, Ghosn et 
al. 2012).  
 
With the exception of immunoglobulins obtained from the naïve B cells; 
all PC-reactive antibodies in this study were extensively mutated. The 
mutations were primarily located in the complementarity determining 
regions (CDRs) of the antibodies and a majority of them were replacement 
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mutations. Antigen driven selection processes are characterized by the 
accumulation of replacement mutations. By consensus, a skewed 
replacement to silent mutation ratio (R/S) of >2.9 in the CDR regions is 
considered indicative of antigen driven affinity maturation (Shlomchik, 
Marshak-Rothstein et al. 1987). In our study, the antibodies generated 
from memory PC+ B cells typically had CDR regions with R/S-ratios of 
>5. These data suggest that human PC-reactive antibodies mainly arise 
from classical antigen-driven immune responses involving somatic 
hypermutation. This discripancy between our data and the prevailing 
paradigm, which is based on mouse data, was unexpected as we had 
hypothesized that the human anti-PC repertoire would be narrow and 
unmutated. However, humans do not live under specific pathogen free 
(SPF) conditions like inbred laboratory mouse strains and the broad anti-
PC repertoire of adult humans that we report in this article, is likely 
reflective of multiple immunological challenges by PC-antigens. While 
our data does not preclude the possibility of a germline encoded innate 
anti-PC in humans, it seems clear that in adults, if present, this putative 
innate response is overshadowed by an adaptive T-independent process 
mediated by conventional B cells. Innate or not, this is still a clinically 
relevant immune response, and multiple studies have consistently 
confirmed that having a low titer of anti-PC is an independent risk factor 
for cardiovascular disease (de Faire, Su et al. 2009, Gronlund, Hallmans 
et al. 2009, Fiskesund, Stegmayr et al. 2010, Caidahl, Hartford et al. 
2012). 
 
Sequencing data from IgG-switched cells, on which we had performed 
single-cell PCR (n=247), identified IgG2 as the predominant subclass 
(64%) among the switched PC-reactive B cells. Sorted and cloned PC-
negative IgG-switched control cells, were as expected mostly IgG1 (59%). 
This skewed subclass distribution towards IgG2 that we report, is 
consistent with previous studies that have characterized the quantity of 
each anti-PC IgG-subclass in human blood (Scott, Briles et al. 1987). 
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4.9 COMPARATIVE ANALYSES OF THE HCDR3 REGION 
The HCDR3 region of an antibody is unique and is often considered to be 
a fingerprint region that can be used to distinguish between different 
clones. Among the hundreds of naïve PC+ cells that we examined, we only 
detected two cells with similar HCDR3. Conversely, within the memory 
compartments of each and every donor, we observed an abundance of 
clonally related B cells with identical VH/D/JH-gene usage and matching 
HCDR3 sequences. This phenomenon was particularly pronounced in the 
IgG-switched and CD27+CD43+ subsets, where a majority (60%) of PC-
reactive B cells had clonal relatives. The lower degree of clonal expansion 
(32%) and hence broader anti-PC repertoire found among IgM+ memory B 
cells might support the hypothesis that this subset constitutes a reservoir 
memory compartment (Defrance, Taillardet et al. 2011). Many of the 
clonally related clusters of B cells that were identified within individual 
donors were dispersed across multiple B cell subsets and this seems to 
suggest a common origin for all three memory subsets.  
 
Whilst comparing antibody HCDR3s from different donors by means of 
alignment with the ClustalW algorithm, we identified 18 idiotypes that 
were present in two or more donors. These highly similar clones found in 
multiple individuals, utilize the same heavy and light chain gene 
configuration and possess strikingly similar HCDR3 and LCDR3 
sequences.  
 
4.10  EXPRESSED HUMAN ANTI-PC MONOCLONALS BIND TO PC  
In order to functionally characterize the properties of human anti-PC 
antibodies, we endeavored to express our most interesting clones as 
recombinant mAbs using a previously published human IgG1-construct 
(Tiller, Meffre et al. 2008). The selection process was primarily focused on 
covering the common idiotype families. Of the 35 expressed antibodies, 34 
bound to PC-conjugated bovine serum albumin (PC-BSA) in ELISA.  
Strong binders constituted 40% of the mAbs and these were primarily 
found among clones from the IgG-switched and CD27+CD43+ subsets. We 
also assayed the polyreactivity profiles of the mAbs using an established 
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ELISA method (Wardemann, Yurasov et al. 2003). Polyreactivity was 
observed in approximately 26% of our human anti-PC mAbs which is in 
the same range of what has been reported for other specificities (Amara, 
Steen et al. 2013).  
 
Using surface plasmon resonance, we determined the affinity of ten mAbs 
to free monomeric PC-hapten and the results were compared with the 
previously reported affinity of mouse TEPC-15 (Gearhart, Johnson et al. 
1981). Several of the tested human mAbs had affinities similar to TEPC-
15. However, a clone from the most prevalent idiotype family (found in 6 
out of 10 indivuals) exhibited an affinity of 2.25x10-7 M, almost 200 times 
greater than the germline mouse TEPC-15 antibody.   
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5 CONCLUDING REMARKS 
The importance of immune cells and inflammation in the development of 
atherosclerosis is now widely accepted. This concept was first conceived 
in the 1980s when inflammatory cells like activated macrophages and T 
cells were detected in atherosclerotic plaques. Subsequent studies have 
proven this theory and thus catalyzed a paradigm shift in the 
cardiovascular field. Along with the new scientific stance on its 
pathogenesis came new ideas about immunomodulatory treatments and 
immunological biomarkers for atherosclerosis.  
 
PC is an epitope that is exposed on oxLDL, apoptotic cells and certain 
human pathogens such as Streptococcus pneumonie. Anti-PC antibodies 
are ubiquitous in mammalian sera and it has been hypothesized that these 
antibodies carry out important functions in homeostasis. This belief stems 
from multiple studies, which have demonstrated the importance of anti-PC 
antibodies in infectious defense and clearance of oxLDL/apoptotic cells. 
Previous studies originating from the Frostegård group have correlated low 
levels of anti-PC IgM with increased incidence of cardiovascular events 
and high levels with slower atherosclerosis progression. This thesis builds 
upon the previous knowledge but has taken the anti-PC concept further by 
consolidating the theory and exploring the molecular ontogeny of human 
anti-PC antibodies.  
 
In paper I, we showed that low level of anti-PC IgM (below the 30th 
percentile) is associated with increased risk of stroke in a large population 
based cohort from northern Sweden. Like in our previous epidemiological 
studies on anti-PC, this association is independent of traditional risk 
factors.  
 
In paper II, we demonstrated that high serum level of anti-PC IgM, IgA 
and IgG1 are associated with decreased atherosclerosis progression. Anti-
PC IgG2 was not correlated to atherosclerosis progression in any way. We 
speculate that this discrepancy could be due to the fact that anti-PC IgG2 
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has a different fine-specificity and that the serum level of anti-PC IgG2 is 
mainly influenced by previous infections by PC-bearing bacteria, which 
we assume is a random event. In paper II, we also showed that the serum 
level of anti-PC IgM does not change much over a period of four years and 
that serum anti-PC IgM could be used in conjunction with serum anti-
MDA or anti-oxLDL IgM to further enhance our ability to predict 
atherosclerosis progression.  
 
The main finding of paper III is that the human anti-PC antibody response 
is heterogeneous though some very similar antibody clones were found in 
multiple study subjects. Furthermore, human anti-PC antibodies were 
discovered to be heavily mutated, including those of the IgM-class, and the 
mutation pattern was indicative of affinity maturation.  
 
Immunomodulation as a treatment option against atherosclerosis and CVD 
has been gaining appreciation among scientist over the last two decades. 
Though the inflammatory nature of atherosclerosis has been broadly 
understood for quite some time now, novel drugs have yet to appear. The 
scientific work in this thesis represents one avenue of research in the quest 
for better diagnostic tools and treatment options for patients with CVD. 
Based on the many promising studies on anti-PC in CVD, natural or 
induced antibodies against PC could potentially be used to treat patients 
with low levels of anti-PC and I believe that the work in this thesis, which 
has focused on understanding the human anti-PC antibody response, is one 
step in that direction. 
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